Cargando…
Targeted next generation sequencing in Chinese colorectal cancer patients guided anti-EGFR treatment and facilitated precision cancer medicine
OBJECTIVE: Colorectal cancer (CRC) patients with both RAS and BRAF wild-type tumors determined by non-next generation sequencing (NGS) testing may still not respond due to the presence of additional mutated genes such as PIK3CA or PTEN. In this study, a broad, hybrid capture-based NGS assay was used...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5739621/ https://www.ncbi.nlm.nih.gov/pubmed/29285234 http://dx.doi.org/10.18632/oncotarget.21349 |
_version_ | 1783287900170878976 |
---|---|
author | Hou, Helei Liu, Dong Zhang, Chuantao Jiang, Yanxia Lu, Guifang Zhou, Na Yang, Xiaonan Zhang, Xiaoping Li, Zhuokun Zhu, Hongmei Qian, Zhaoyang Zhang, Xiaochun |
author_facet | Hou, Helei Liu, Dong Zhang, Chuantao Jiang, Yanxia Lu, Guifang Zhou, Na Yang, Xiaonan Zhang, Xiaoping Li, Zhuokun Zhu, Hongmei Qian, Zhaoyang Zhang, Xiaochun |
author_sort | Hou, Helei |
collection | PubMed |
description | OBJECTIVE: Colorectal cancer (CRC) patients with both RAS and BRAF wild-type tumors determined by non-next generation sequencing (NGS) testing may still not respond due to the presence of additional mutated genes such as PIK3CA or PTEN. In this study, a broad, hybrid capture-based NGS assay was used to identify RAS, BRAF and additional targetable genetic alterations from Chinese CRC tissues. METHODS: Fifty-seven cases of CRC were enrolled, and all the patients signed the informed consent. In total, 7708 exons of 508 tumor-related genes and 78 introns of 19 frequently rearranged genes were assessed for base substitutions, INDELs, copy number alterations, and gene fusions. RESULTS: The study found that 50.9% (29/57) of the tumors harbored KRAS mutations, 3.5% (2/57) harbored NRAS mutations and 3.5% (2/57) harbored BRAF mutations. More specifically, 89.7% (26/29) of RAS mutations were located in codon 12. Except for RAS and RAF, anti-EGFR therapy response genetic mutations in PTEN (n=2) and PIK3CA (n=1) were found in 4.7% (3/64) of the samples. Actionable alterations were found in HER2 (n = 7), CCND2 (n = 2), NF1 (n = 1), and BRCA1 (n = 1). CONCLUSIONS: Our results illustrated that 82.5% (47/57) of the samples harbored at least one actionable genetic alteration identified by NGS. HER2 amplifications or mutations, which were identified in 12.3% of the tissues, defined a unique molecular subtype of CRC. The study suggests that high-throughput NGS testing in CRC tissues is a comprehensive and efficient genomic profiling assay to guide personalized therapy. |
format | Online Article Text |
id | pubmed-5739621 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-57396212017-12-28 Targeted next generation sequencing in Chinese colorectal cancer patients guided anti-EGFR treatment and facilitated precision cancer medicine Hou, Helei Liu, Dong Zhang, Chuantao Jiang, Yanxia Lu, Guifang Zhou, Na Yang, Xiaonan Zhang, Xiaoping Li, Zhuokun Zhu, Hongmei Qian, Zhaoyang Zhang, Xiaochun Oncotarget Research Paper OBJECTIVE: Colorectal cancer (CRC) patients with both RAS and BRAF wild-type tumors determined by non-next generation sequencing (NGS) testing may still not respond due to the presence of additional mutated genes such as PIK3CA or PTEN. In this study, a broad, hybrid capture-based NGS assay was used to identify RAS, BRAF and additional targetable genetic alterations from Chinese CRC tissues. METHODS: Fifty-seven cases of CRC were enrolled, and all the patients signed the informed consent. In total, 7708 exons of 508 tumor-related genes and 78 introns of 19 frequently rearranged genes were assessed for base substitutions, INDELs, copy number alterations, and gene fusions. RESULTS: The study found that 50.9% (29/57) of the tumors harbored KRAS mutations, 3.5% (2/57) harbored NRAS mutations and 3.5% (2/57) harbored BRAF mutations. More specifically, 89.7% (26/29) of RAS mutations were located in codon 12. Except for RAS and RAF, anti-EGFR therapy response genetic mutations in PTEN (n=2) and PIK3CA (n=1) were found in 4.7% (3/64) of the samples. Actionable alterations were found in HER2 (n = 7), CCND2 (n = 2), NF1 (n = 1), and BRCA1 (n = 1). CONCLUSIONS: Our results illustrated that 82.5% (47/57) of the samples harbored at least one actionable genetic alteration identified by NGS. HER2 amplifications or mutations, which were identified in 12.3% of the tissues, defined a unique molecular subtype of CRC. The study suggests that high-throughput NGS testing in CRC tissues is a comprehensive and efficient genomic profiling assay to guide personalized therapy. Impact Journals LLC 2017-09-27 /pmc/articles/PMC5739621/ /pubmed/29285234 http://dx.doi.org/10.18632/oncotarget.21349 Text en Copyright: © 2017 Hou et al. http://creativecommons.org/licenses/by/3.0/ This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) (CC-BY), which permits unrestricted use and redistribution provided that the original author and source are credited. |
spellingShingle | Research Paper Hou, Helei Liu, Dong Zhang, Chuantao Jiang, Yanxia Lu, Guifang Zhou, Na Yang, Xiaonan Zhang, Xiaoping Li, Zhuokun Zhu, Hongmei Qian, Zhaoyang Zhang, Xiaochun Targeted next generation sequencing in Chinese colorectal cancer patients guided anti-EGFR treatment and facilitated precision cancer medicine |
title | Targeted next generation sequencing in Chinese colorectal cancer patients guided anti-EGFR treatment and facilitated precision cancer medicine |
title_full | Targeted next generation sequencing in Chinese colorectal cancer patients guided anti-EGFR treatment and facilitated precision cancer medicine |
title_fullStr | Targeted next generation sequencing in Chinese colorectal cancer patients guided anti-EGFR treatment and facilitated precision cancer medicine |
title_full_unstemmed | Targeted next generation sequencing in Chinese colorectal cancer patients guided anti-EGFR treatment and facilitated precision cancer medicine |
title_short | Targeted next generation sequencing in Chinese colorectal cancer patients guided anti-EGFR treatment and facilitated precision cancer medicine |
title_sort | targeted next generation sequencing in chinese colorectal cancer patients guided anti-egfr treatment and facilitated precision cancer medicine |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5739621/ https://www.ncbi.nlm.nih.gov/pubmed/29285234 http://dx.doi.org/10.18632/oncotarget.21349 |
work_keys_str_mv | AT houhelei targetednextgenerationsequencinginchinesecolorectalcancerpatientsguidedantiegfrtreatmentandfacilitatedprecisioncancermedicine AT liudong targetednextgenerationsequencinginchinesecolorectalcancerpatientsguidedantiegfrtreatmentandfacilitatedprecisioncancermedicine AT zhangchuantao targetednextgenerationsequencinginchinesecolorectalcancerpatientsguidedantiegfrtreatmentandfacilitatedprecisioncancermedicine AT jiangyanxia targetednextgenerationsequencinginchinesecolorectalcancerpatientsguidedantiegfrtreatmentandfacilitatedprecisioncancermedicine AT luguifang targetednextgenerationsequencinginchinesecolorectalcancerpatientsguidedantiegfrtreatmentandfacilitatedprecisioncancermedicine AT zhouna targetednextgenerationsequencinginchinesecolorectalcancerpatientsguidedantiegfrtreatmentandfacilitatedprecisioncancermedicine AT yangxiaonan targetednextgenerationsequencinginchinesecolorectalcancerpatientsguidedantiegfrtreatmentandfacilitatedprecisioncancermedicine AT zhangxiaoping targetednextgenerationsequencinginchinesecolorectalcancerpatientsguidedantiegfrtreatmentandfacilitatedprecisioncancermedicine AT lizhuokun targetednextgenerationsequencinginchinesecolorectalcancerpatientsguidedantiegfrtreatmentandfacilitatedprecisioncancermedicine AT zhuhongmei targetednextgenerationsequencinginchinesecolorectalcancerpatientsguidedantiegfrtreatmentandfacilitatedprecisioncancermedicine AT qianzhaoyang targetednextgenerationsequencinginchinesecolorectalcancerpatientsguidedantiegfrtreatmentandfacilitatedprecisioncancermedicine AT zhangxiaochun targetednextgenerationsequencinginchinesecolorectalcancerpatientsguidedantiegfrtreatmentandfacilitatedprecisioncancermedicine |